<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Health technology assessment (debate) - Wednesday, 13 February 2019</title><meta name="title" content="Verbatim report of proceedings - Health technology assessment (debate) - Wednesday, 13 February 2019" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2019 - Source: European Parliament" /><meta name="available" content="13-02-2019" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Health technology assessment (debate) - Wednesday, 13 February 2019" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2019-02-13-ITM-014_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2019-02-13-ITM-014_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2019-02-13-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2019-02-13-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2019-02-13-ITM-013_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2019-02-13-ITM-013_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2019-02-13-ITM-015_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2019-02-13-ITM-015_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2019-02-13_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2019-02-13_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2018/0018(COD)">2018/0018(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A8-0289/2018</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-8-2018-0289_EN.html" class="ring_ref_link">A8-0289/2018</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-8-2018-10-01-ITM-016_EN.html" class="ring_ref_link">PV 01/10/2018 - 16</a><br />
                        <a href="/doceo/document/CRE-8-2018-10-01-ITM-016_EN.html" class="ring_ref_link">CRE 01/10/2018 - 16</a><br />
                        <a href="/doceo/document/PV-8-2019-02-13-ITM-014_EN.html" class="ring_ref_link">PV 13/02/2019 - 14</a><br />
                        <a class="ring_ref_selected">CRE 13/02/2019 - 14</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-8-2018-10-03-ITM-009-04_EN.html" class="ring_ref_link">PV 03/10/2018 - 9.4</a><br />
                        <a href="/doceo/document/CRE-8-2018-10-03-ITM-009-04_EN.html" class="ring_ref_link">CRE 03/10/2018 - 9.4</a><br />
                        <a href="/doceo/document/CRE-8-2018-10-03-ITM-010-02_EN.html" class="ring_ref_link">Explanations of votes</a><br />
                        <a href="/doceo/document/PV-8-2019-02-14-ITM-010-06_EN.html" class="ring_ref_link">PV 14/02/2019 - 10.6</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-8-2018-0369_EN.html" class="ring_ref_link">P8_TA(2018)0369</a><br />
                        <a href="/doceo/document/TA-8-2019-0120_EN.html" class="ring_ref_link">P8_TA(2019)0120</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 13 February 2019 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 14. Health technology assessment (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:23:20&amp;playerEndTime=20190213-16:58:01" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:23:20&amp;playerEndTime=20190213-16:58:01" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:23:20&amp;playerEndTime=20190213-16:58:01" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-8-2019-02-13-ITM-014_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-8-2019-02-13-ITM-014_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-8-2019-02-13-ITM-014_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="3-435-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/33984.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:23:20&amp;playerEndTime=20190213-16:24:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Președintele. – </span></span>  Următorul punct de pe ordinea de zi este dezbaterea privind raportul lui Soledad Cabezón Ruiz, în numele Comisiei pentru mediu, sănătate publică și siguranță alimentară, referitor la propunerea de regulament al Parlamentului European și al Consiliului privind evaluarea tehnologiilor medicale și de modificare a Directivei 2011/24/UE (<a href="https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&amp;lg=EN&amp;type_doc=COMfinal&amp;an_doc=2018&amp;nu_doc=0051">COM(2018)0051</a> – C8-0024/2018 – <a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2018/0018(COD)">2018/0018(COD)</a>) (<a href="/doceo/document/A-8-2018-0289_EN.html">A8-0289/2018</a>).</p>
<p class="contents">Vreau înainte să fac următoarea precizare: cartonașele albastre nu vor fi permise, iar, în ceea ce privește <span class="italic">catch the eye</span>, în funcție de timp, pentru că, la ora 17.00, știți foarte bine, avem voturi și trebuie să respectăm foarte strict orarul ca să ne încadrăm în acest timp. Deci, <span class="italic">catch the eye</span> vom evalua când vedem cum stăm cu timpul și rog fiecare vorbitor să se încadreze în timp.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-436-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:24:01&amp;playerEndTime=20190213-16:30:02" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz, </span></span>  <span class="italic">ponente</span><span class="bold">.</span> – Señor presidente, señor comisario, comienzo reiterando mi reconocimiento de que una propuesta europea de una agencia evaluadora de tecnologías sanitarias es oportuna y que vendría a hacer «más Europa». Es cierto que la normativa europea en medicamentos desarrollada desde el año 1965, a raíz del desastre de la talidomida, ha contribuido de forma importante a la mejora de los estándares de salud en la Unión Europea y que también, al mismo tiempo, hoy consideramos que tiene ámbitos de mejora.</p>
<p class="contents">La Agencia Europea de Medicamentos evalúa y autoriza los medicamentos en base a la eficacia y a la seguridad, sin tener en cuenta la calidad en términos de efectividad o el valor terapéutico añadido. Alguien —como yo— podría considerar incluso que quizá no sea ético, además de que pueda suponer una cargar de sostenibilidad a los sistemas sanitarios.</p>
<p class="contents">Pero lo cierto es que el Parlamento, haciéndose eco de la ciudadanía, quiere garantizar el acceso a los medicamentos, a la tecnología sanitaria. Los altos precios en el contexto de la crisis fueron el detonante de estas dificultades en el acceso, pero también hay falta de adecuación entre la investigación y las necesidades médicas, y también se precisa de más calidad. Hay un exceso de investigación incremental en detrimento de innovaciones genuinas; algunos estudios las cifran en el 85 %. Además, ni siquiera los altos precios de los medicamentos van de la mano del alto valor terapéutico añadido en muchos casos.</p>
<p class="contents">En el caso, en concreto, de los medicamentos oncológicos, que han visto multiplicarse su precio por más de diez, solamente han demostrado un 15 % de ellos mostrar un incremento en la supervivencia a los 5 años.</p>
<p class="contents">Los Estados miembros han venido realizando esta evaluación de calidad como parte del proceso de establecimiento de precios y reembolso. La Comisión Europea, desde el año 2003, a través de la EUnetHTA ha financiado la colaboración entre estos para aproximar criterios, metodología, mejorar e incrementar la evidencia clínica y establecer el valor clínico de la tecnología sanitaria.</p>
<p class="contents">Además, los avances en genética, los últimos medicamentos destinados a poblaciones cada vez más pequeñas, las terapias avanzadas o la propia tecnología precisan cada vez de una evidencia clínica más exigente, y suficiente en todo caso para poder tomar decisiones al respecto.</p>
<p class="contents">Sin embargo, a pesar de la consideración positiva por parte de los Estados miembros de esta colaboración voluntaria, no han hecho uso de la misma. El Parlamento Europeo considera necesario también ahondar en esta colaboración y pasar a un escenario de estabilidad, con un procedimiento reglamentado y con financiación pública que mejore el acceso a la tecnología sanitaria por la ciudadanía europea, contribuya a la sostenibilidad de los sistemas sanitarios e incremente la calidad de la investigación, alineando también con las necesidades los pacientes esta investigación.</p>
<p class="contents">La Comisión Europea nos presentó una propuesta de HTA, justificándola en la necesidad de mejorar el funcionamiento del mercado interior y con ello la predictibilidad de la industria. Aun siendo cierto que pueda existir distorsión en el mercado interior, este no puede ser el objetivo principal de la propuesta, toda vez, incluso, que esta distorsión puede corresponder en gran parte a la concepción del propio medicamento como un bien de consumo más y que se rige por las leyes del mercado. No obstante, este Reglamento tampoco se tiene por qué oponer —y es posible que pueda contribuir— a esa mejora de la competitividad de la industria, estimulando una innovación de calidad y mejorando la eficiencia de la investigación.</p>
<p class="contents">La posición del Parlamento ha venido a dar una respuesta, a mi modo de ver bastante equilibrada, a todos estos retos que he planteado y, ante todo, buscando la necesaria confianza en el proceso, garantizando independencia, transparencia, objetividad, calidad científica y validación externa de todo el procedimiento. Todo ello permitiendo un claro protagonismo y control por parte de los Estados miembros a través de sus agencias nacionales de evaluación del proceso. Y, en última instancia, garantizando que, aunque la evaluación clínica pueda ser global, la decisión finalmente sea local.</p>
<p class="contents">Los Estados miembros podrán llevar a cabo sus propias reevaluaciones para adaptarlas a sus contextos nacionales, dentro de las competencias nacionales del sistema de establecimiento de precios y reembolsos, que incluye criterios clínicos específicos además de sociales, éticos y económicos, alejando las dudas sobre posibles efectos negativos en la sostenibilidad de los sistemas nacionales de salud, como se nos ha ido mostrando.</p>
<p class="contents">Al mismo tiempo, abre nuevos ámbitos de colaboración en sectores emergentes en salud como es la medicina de precisión o la desinversión de tecnología obsoleta. En definitiva, —como decía— una propuesta equilibrada, oportuna y garantista con los pacientes y también con los sistemas nacionales de salud. Por lo tanto, a mi modo de ver, necesaria.</p>
<p class="contents">Ahora se precisa de una postura constructiva y dialogante por parte de los Estados miembros, a lo que este Parlamento siempre se ha mostrado abierto. Lo contrario puede suponer bloquear la necesaria discusión para mejorar el acceso a la tecnología sanitaria por parte de los pacientes en la Unión Europea.</p>
<p class="contents">No es bueno una postura obcecada, en contra y sin diálogo ni alternativas por parte de determinados países, que solo nos puede llevar a repetir experiencias previas con otros dosieres en salud que solamente acaban con el resultado de que los únicos que acaban perdiendo son los pacientes.</p>
<p class="contents">Este Parlamento ha trabajado duro y rápido para poder cerrar este dosier en la presente legislatura y enviar un mensaje muy importante a la ciudadanía europea, que nos viene pidiendo mejoras en el acceso a los medicamentos, a la tecnología sanitaria; que tiene a la salud entre sus prioridades, como demuestra de forma reiterada el Eurobarómetro, y que nos evaluará en los próximos meses en las urnas.</p>
<p class="contents">Por todo ello, apelo a una posición constructiva por parte de los Estados miembros para poder cerrar este dosier y dar esa respuesta que nos pide la ciudanía europea.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-437-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:30:04&amp;playerEndTime=20190213-16:36:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Mr President, I am very pleased to have this opportunity to discuss the Commission proposal for a regulation on health technology assessment. Parliament has shown very active and constructive engagement on this file, which led to the adoption of the ENVI Committee report in Plenary on 3 October last. Once again, I would like to congratulate Ms Cabezón Ruiz for her excellent and timely work as rapporteur for this file. I also want to reiterate my thanks to the shadow rapporteurs, Ms Grossetete, Ms Meissner, Ms Konečná and others as well as the ENVI Committee, the Committee on Industry Research and Energy and the Committee on Internal Market and Consumer Protection. Regrettably, negotiations between the institutions have not yet commenced, but the adoption of Parliament’s formal first reading position would send a clear signal on the importance of continuing to work on this file as we move towards the end of this mandate and onwards into the next one. The Commission appreciates Parliament’s overall support for its proposal, including a clear and ambitious product scope on medicinal products and medical devices. While time does not allow me to comment in detail on all the various amendments, I want to echo some of the points made by the Commission in October.</p>
<p class="contents">First, on the issue of the national use of European joint clinical assessments, the Commission welcomes Parliament’s strong support in ensuring that joint clinical assessments will be used by Member States and will not be repeated. The approach suggested by Parliament to add some qualification as to the meaning of non-duplication of European clinical assessments at national level has been helpful in the ongoing discussions in the Council. While the issue is still open, it needs further discussion. It takes a step towards addressing the concerns expressed by some Member States. Parliament has also added that the legislation should not prevent Member States from conducting complementary clinical assessments outside the scope of the joint clinical assessment. I am ready to support such an approach.</p>
<p class="contents">Other amendments were aimed at further qualifying the proposal. They stress that Member States continue to be responsible for drawing their own conclusions on the added therapeutic value of health technologies in the context of their healthcare and cure systems.</p>
<p class="contents">The second general area I would like to comment on concerns the respective roles of the Commission and the Member States in the cooperation process. In this area the amendments follow the spirit of the text as they aim to clarify the Members States’ responsibility for conducting the joint work and the supporting role of the Commission.</p>
<p class="contents">The third important area relates to the quality and transparency of joint work produced through EU cooperation. The proposed amendment should ensure the submission of appropriate evidence by technology developers and provide for a high scientific quality, independence and transparency in the joint work.</p>
<p class="contents">There were important objectives of the Commission’s proposal and I’m convinced that the real added value of strengthened cooperation on HTA at EU level lies in the quality of joint clinical assessments. Together we are all much stronger.</p>
<p class="contents">Lastly, let me stress that the Commission has concerns when it comes to the removal of the harmonisation of national rules related to clinical assessment. This was one important element of our proposal, notably to improve the functioning of the internal market while contributing to a high level of human health protection. In proposing such harmonisation of national HTA methodologies, we had actually responded to the previous calls for action from Parliament. Among those calls I remember that your resolution on access to medicines called for the harmonisation of HTA tools and methodologies, and it’s clear.</p>
<p class="contents">I would like to conclude by stressing that the Commission welcomes Parliament’s constructive proposals and stands ready to continue to discuss and explore solutions to outstanding issues with the co-legislators. The Commission is currently fully engaged in the discussions in the Council as these continue to progress and we welcome the Romanian Presidency’s commitment to move the discussion forward. The HTA proposal is expected to lead to a saving and benefits for all key actors. It will support Member States in their investment decisions to prioritising truly innovative technologies. National authorities will be able to pool their expertise and avoid duplication of efforts, making better use of human and financial resources. Industry will benefit from clearer rules and greater predictability for their business planning, as well as cost savings. The healthcare sector accounts for approximately 10% of European Union GDP or 1 300 billion per year. But, above all, this proposal is about European citizens, about European patients. Patients are at the heart of this proposal, which aims to deliver more efficient, transparent and effective European Union HTA. The new model of EU cooperation has a clear potential to facilitate better access to innovative health technologies. Yesterday we discussed issues about women and cancer, about possibilities to guarantee access to new treatments and HTA is a tool which can help us address these issues.</p>
<p class="contents">I therefore call on you to help make this initiative a success. I look forward to hearing your views.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-438-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/183022.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:36:29&amp;playerEndTime=20190213-16:37:59" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lieve Wierinck, </span></span>  <span class="italic">rapporteur voor advies ITRE</span><span class="bold">.</span> – Voorzitter, met deze nieuwe wetgeving zetten we een stap in de goede richting, en wel om drie redenen.</p>
<p class="contents">Ten eerste hebben patiënten met een zeldzame kanker of een zeldzame ziekte dankzij deze Europese samenwerking meer kans op de beschikbaarheid van een geneesmiddel dat werkt. Mits de nodige privacybescherming zullen de lidstaten toegang krijgen tot grootschalige onderzoeksgegevens.</p>
<p class="contents">Ten tweede zorgt de klinische evaluatie van nieuwe gezondheidstechnologie ervoor dat de lidstaten op de hoogte worden gehouden van de ontwikkelingen op de markt, en van het feit of deze producten beter werken dan degene die reeds op de markt aanwezig zijn. Door innovatieve ontwikkelingen beter in de kijker te zetten stimuleren wij onze gezondheidssector op Europees niveau.</p>
<p class="contents">Ten derde ben ik tevreden dat de flexibiliteit blijft bestaan, zowel voor de lidstaat als voor de coördinatiegroep die de evaluatie samenstelt. De lidstaten beslissen of er een terugbetalingssysteem voor deze nieuwe technologie komt. De coördinatiegroep behoudt het overzicht over welke nieuwe technologieën baanbrekend zijn.</p>
<p class="contents">Als we voluit de kaart trekken van onderzoek en innovatie voor Europa en daarbij de patiënt centraal stellen, dan is een Europese evaluatie van gezondheidstechnologieën dé weg die we moeten gaan, samen met de lidstaten.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-439-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/38420.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:38:01&amp;playerEndTime=20190213-16:39:10" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Cristian-Silviu Buşoi, </span></span>  <span class="italic">rapporteur for the opinion of the Committee on the Internal Market and Consumer Protection</span><span class="bold">.</span> – Mr President, as I mentioned previously, I welcome the new proposal aimed at strengthening EU cooperation on health technology assessment. I’d like to thank Ms Cabezón Ruiz and my colleagues for the close collaboration.</p>
<p class="contents">I believe that joint clinical assessment should be done at EU level in order to shorten the process and provide faster access to innovative drugs for all patients in the EU without jeopardising the final decision of the Member States. As the rapporteur in the Committee on the Internal Market and Consumer Protection, I took particular interest in two main objectives of the proposal: to increase the level of human health protection and to ensure better functioning of the internal market. We amended the proposal so that health technology developers would have the possibility to request an update of the clinical assessment where additional evidence from clinical practices became available, and we also asked for a flexible mechanism to introduce innovative technologies and treatments for patients. I support adoption at first reading. I hope that under Romaniaʼs Presidency an agreement will be reached, but I’m sure that the Romanian Presidency will achieve important progress.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-440-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:39:14&amp;playerEndTime=20190213-16:40:50" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête, </span></span>  <span class="italic">au nom du groupe PPE</span><span class="bold">.</span> – Monsieur le Président, les traités nous le rappellent: la mission de l’Europe en matière de santé est de permettre à tous un égal accès à des soins de qualité.</p>
<p class="contents">Alors, comment comprendre que la valeur ajoutée clinique d’un médicament autorisé dans toute l’Europe diffère d’un pays à l’autre? Comment expliquer aux patients qu’un même traitement soit jugé innovant, utile et efficace de l’autre côté de la frontière, alors qu’il est considéré comme ayant une moindre valeur ajoutée dans son pays? Comment annoncer à un patient qu’il doit encore attendre pour obtenir ce nouveau médicament qui est déjà disponible dans le pays voisin?</p>
<p class="contents">Ne nous y trompons pas. Il ne s’agit pas de parler de prix et de remboursement mais de conduire en commun une évaluation scientifique portant sur la valeur ajoutée thérapeutique d’une nouvelle technologie, par rapport aux alternatives existantes, et cela pour favoriser les traitements à plus forte valeur ajoutée, permettre les décisions budgétaires des États membres et accélérer l’accès des patients aux innovations médicales et puis aussi éviter la duplication du travail; cela ferait perdre toute sa valeur ajoutée à notre procédure commune.</p>
<p class="contents">Je regrette que les réticences des États membres ne nous aient pas permis d’avancer plus vite sur ce texte essentiel. Grâce à notre rapporteur, nous avions pourtant adopté en septembre un texte raisonnable qui devait aider à surmonter ces divergences. J’appelle aujourd’hui le Conseil à penser aux patients auxquels une solidarité européenne accrue en matière de santé ne peut que bénéficier.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-441-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:40:52&amp;playerEndTime=20190213-16:42:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan, </span></span>  <span class="italic">u ime kluba S&amp;D</span><span class="bold">.</span> – Gospodine predsjedavajući, reforma sustava procjene zdravstvenih tehnologija jedan je od glavnih zahtjeva iz Izvještaja o pristupu lijekovima kojeg smo donijeli 2016. godine. </p>
<p class="contents">Drago mi je što je Komisija, unatoč negativnim signalima nekih država članica, prepoznala potencijal proširenog i reformiranog HTA sustava. Koristi od tješnje suradnje nacionalnih i regionalnih HTA tijela u konačnici će imati svi: pacijenti, farmaceuti, liječnici i zdravstveni sustavi. Nova platforma državama članicama i njihovim tijelima uštedjet će vrijeme i novac jer će se izbjeći nepotrebno ponavljanje procjena koje su druge države već napravile. To se pogotovo odnosi na zemlje koje imaju male HTA kapacitete. </p>
<p class="contents">Nažalost, ovi argumenti nisu bili dovoljni državama članicama u Vijeću. Kada su zdravlje i zdravstvo u pitanju, vrijeme nije novac, već život i zato moram izraziti nezadovoljstvo odbijanjem Vijeća da započne pregovore. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-442-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96870.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:42:03&amp;playerEndTime=20190213-16:44:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gesine Meissner, </span></span>  <span class="italic">im Namen der ALDE-Fraktion</span><span class="bold">.</span> – Herr Präsident, Herr Kommissar, meine lieben Kolleginnen und Kollegen! Es ist tatsächlich so, dass wir eine sehr gute Zusammenarbeit bei dieser Gesetzgebung im Parlament hatten, und ich möchte mich ganz herzlich bedanken. Das war konstruktiv, und das war auch wirklich sehr wichtig. </p>
<p class="contents">Denn es ist jetzt so: Was haben wir erreicht? Dass der Zugang für Patienten zu Arzneimitteln schneller sein soll, weil wir dezentral eine Zulassung haben wollen. Es macht überhaupt keinen Sinn, dass wir eben statt nur einmal zentral das bis zu 28 Mal – wie es im Moment noch ist – durchziehen. Das ist wirklich nichts, was wir brauchen.</p>
<p class="contents">Und im Prinzip profitieren von dieser Vereinfachung sowohl die Patienten als auch Behörden, Wissenschaftler – eigentlich alle, auch die Hersteller. Es ist trotzdem so, dass die Skepsis der Mitgliedstaaten erst sehr stark war. Also gerade große Mitgliedstaaten wie meiner – Deutschland – und auch Spanien haben protestiert und haben gesagt: Das ist nichts, was die EU-Ebene angeht. Ich denke, sie liegen da ganz falsch. Es ist wichtig, dass alle, auch die kleinen Länder, die vielleicht nicht ganz so starke Forschung haben, profitieren können, dass die Menschen überall in der EU von einer zentralen Zulassung profitieren können. Darum, denke ich, ist es vollkommen gut, dass wir dieses Gesetz jetzt haben.</p>
<p class="contents">Mir war von vornherein wichtig, zum einen schon zu sehen, wo die Mitgliedstaaten vielleicht selber auch Kompetenzen brauchen, und zum anderen auch zu sehen, was mit den Medizinprodukten ist. Ich war Berichterstatterin, genau wie Frau Kollegin Borzan, bei der Medizinprodukteverordnung. Und da haben wir nun gerade vor einem Jahr etwas verabschiedet, was für die Medizinprodukte mehr Sicherheitsstandard, bessere Anforderungen an Leistungsfähigkeit usw. geben soll – unabhängig von ihrer Klasse. Auch den klinischen Mehrwert haben wir drin. Und da sah ich nicht ein, dass wir jetzt – bevor das Ganze umgesetzt ist – schon bei der HTA die gleichen Anforderungen stellen sollen. Mir wäre es daher am liebsten gewesen, wir hätten gesagt: Wir machen hier ein starkes Gesetz für Arzneimittel, und die Medizinprodukte, die betrachten wir später.</p>
<p class="contents">Das war jetzt nicht ganz Kompromisslinie. Aber wir haben einen – finde ich – sehr guten Kompromiss gefunden, in dem wir die Anwendung auf die Medizinprodukte sehr stark eingeengt haben.</p>
<p class="contents">Ich möchte noch etwas Weiteres ansprechen, das wurde noch nicht benannt, was im Kommissionsvorschlag nicht drin war: Das waren Methoden, die man für die Durchführung von HTA skizzieren kann. Die sind jetzt drin. Das sind teilweise schon bewährte Methoden, und ich denke, das ist gut für die Mitgliedstaaten und deren Experten, die daran arbeiten sollen.</p>
<p class="contents">Als Letztes: Wichtig ist auch, dass wir jetzt nationale Bewertungssysteme berücksichtigt haben, die teilweise unterschiedlich sind. Bei der Erstattungsgrundlage zum Beispiel gibt es verschiedene Definitionen von Überleben und Lebensqualität. Das ist nicht überall gleich gewichtet, und darum muss man auch zusätzlich nationale Kriterien ohne Dopplung – wohlgemerkt – durchführen können. </p>
<p class="contents">Schade, dass die Mitgliedstaaten uns nicht folgen, sonst könnten wir verhandeln. Das wäre gut für die Patienten in Europa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-443-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23699.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:44:52&amp;playerEndTime=20190213-16:46:32" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kateřina Konečná, </span></span>  <span class="italic">za skupinu GUE/NGL</span><span class="bold">.</span> – Pane předsedající, pane komisaři, v prvé řadě musím říct, že jsem současným stavem extrémně zklamaná. Varianta, ve které jsme dokument odhlasovali, je sama o sobě dosti oslabená. A návrh se zaměřuje čistě jen na klinická hodnocení. Došlo k vyřazení jak ekonomických, sociálních, tak i etických aspektů. Taktéž jsme zakotvili extrémně dlouhé přechodné období, po které se členské státy nebudou muset systému vůbec účastnit. Naše řešení společných hodnocení zdravotnických prostředků v podstatě znamená zastřené vyjmutí zdravotnických prostředků ze systému. Zjevně ale i toto přijde členským státům příliš málo. Sama tak začínám pochybovat, jestli vůbec má smysl tento návrh dále projednávat, neboť pokud by došlo ještě k dalšímu jeho oslabení ze strany členských států, nakonec asi bude lepší zůstat u současné dobrovolné spolupráce. </p>
<p class="contents">Přitom evropští pacienti zoufale čekají na tuto novou úpravu a jsou rozhořčeni i naším odsunem povinného hodnocení o řadu let. Pacientské organizace zcela oprávněně očekávají, že budou více zapojeny do procesu hodnocení. Také námi přijaté výjimky pro rychlejší přístup pacientů k lékům na vzácná onemocnění je nezbytné uvést co nejrychleji do praxe, protože úspěšný boj se vzácnými onemocněními je bytostně přeshraniční záležitostí.</p>
<p class="contents">Členské státy v čele s rakouským a rumunským předsednictvím by se měly stydět. Nezbývá nám nic jiného, než potřebný dokument posunout do nového období, což je ostuda. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-444-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1927.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:46:35&amp;playerEndTime=20190213-16:48:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Peter Liese (PPE).</span></span>   – Herr Präsident, liebe Kolleginnen und Kollegen! Können Sie sich vorstellen, dass ein neues Krebsmedikament, das neu auf den Markt kommt und von der Europäischen Arzneimittelagentur positiv bewertet wurde, in Frankreich das Leben der Patienten um ein Jahr verlängert, in Deutschland um zwei Jahre, und in Italien gar nicht? Ich kann mir das nicht vorstellen. Zum Glück gibt es nationale Unterschiede, Mentalitätsunterschiede, aber was die Wirkung von Medikamenten angeht, sind wir Europäer doch ziemlich ähnlich.</p>
<p class="contents">Deswegen muss es doch möglich sein, diesen wissenschaftlichen Teil der Bewertung in Europa einheitlich zu tun. Es ist eine Verschwendung von Ressourcen, wenn sowohl die Behörden der Mitgliedstaaten als auch die Unternehmen oder sonstige Antragsteller das 26, 27 Mal machen müssen. Deswegen bin ich nach wie vor der Meinung, dass die Kommission einen guten Vorschlag gemacht hat und das Parlament dazu auch eine kluge Stellungnahme abgegeben hat.</p>
<p class="contents">Wir sollten nicht übertreiben, Kollegin Konečná: Die ethische Bewertung ist Sache der Mitgliedstaaten – die Mitgliedstaaten haben ja eine starke Kompetenz –, aber was die wissenschaftliche Bewertung angeht, muss das doch möglich sein.</p>
<p class="contents">Ich bedaure, dass der Rat sich dazu nicht bereitgefunden hat. Wir haben alle legitimen Anliegen des Rates in unsere Beschlussfassung aufgenommen, und deswegen ist es schade, dass wir morgen diesen Beschluss fassen müssen. Aber wir sollten weiter Druck ausüben. Dieser Vorschlag darf nicht sterben, sondern muss irgendwann beschlossen werden.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-445-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124847.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:48:14&amp;playerEndTime=20190213-16:49:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Gentile (S&amp;D).</span></span>   – Signor Presidente, onorevoli colleghi, signor Commissario, la ricerca, l'innovazione e la nuova e buona economia si incrociano per raggiungere un obiettivo qualificante, quello di un'Europa che rimette al centro le persone e i loro diritti. Pensare a modelli di valutazione che semplificano le procedure significa guadagnare tempo e qualità, evitando duplicazioni e sovrapposizioni, garantendo esiti della stessa fondati sulla condivisione dei percorsi dentro una griglia di parametri di qualità, avendo appunto a disposizione un bouquet di buone prassi riconosciute come tali. </p>
<p class="contents">L'autorizzazione centralizzata, dunque, è l'obiettivo di questa proposta che incontra la domanda di qualità, che migliora la performance complessiva dei percorsi di ricerca e di sperimentazione clinica e che contribuisce a rendere compatibile l'obiettivo di sostenibilità dei costi dei sistemi sanitari con l'efficacia delle cure, rendendo accessibili tecnologie e farmaci destinati alla diagnosi e alla cura anche di patologie complesse e rare che mettono a dura prova sistemi sanitari, pazienti e famiglie. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-446-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125101.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:49:29&amp;playerEndTime=20190213-16:51:15" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Inácio Faria (PPE).</span></span>   – Mr President, proper health technology assessment (HTA) can be the unbiased tipping point for the game-changing technologies available for patients. This is a matter of supranational interest for European citizens and cannot be weighed only by economic factors. Assessments, pricing and reimbursement can be set as a touchstone for the sustainability of health systems. So far, this is the only tool able to ensure that citizens have affordable and effective treatments vis-à-vis the values demanded by profit-making manufacturers. However, the reality shows that HTA is fragmented throughout Europe. In fact, by reaching different outcomes, these assessments leave citizens and health professionals with different spans of choice, according to their Member States. Here, you can also count on us to fight for equal opportunities.</p>
<p class="contents">This proposal relies on the collaboration of Member States but still leaves room for national decisions. By centralising the clinical assessment we can avoid duplication, save resources and, above all, create a European Union with less asymmetry in access to health care. This proposal is only effective with the combined efforts of the national regulatory agencies and I greatly salute the integration of patient representatives in the assessment procedure.</p>
<p class="contents">This will make HTA involved from mere farmer ecological data on to a more realistic evaluation. That weights the contributions to the patients’ quality of life. But for the assessments to be beyond any doubt, they need to be as transparent as possible. This is the only way to build confidence in the health technology chain of value.</p>
<p class="contents">I hope this regulation will bring us closer to the united, safe and healthy Europe we all long for.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-447-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97014.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:51:15&amp;playerEndTime=20190213-16:52:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Karin Kadenbach (S&amp;D).</span></span>   – Herr Präsident! Die Zulassung von Medikamenten und medizinischem Gerät muss europaweit einheitlicher und entlang nachvollziehbarer wissenschaftlicher Kriterien gebündelt werden. Durch den Wildwuchs verschiedenster nationaler Regelungen für die medizinische Bewertung werden manche Produkte in dem einen Mitgliedstaat früher zugelassen, schneller zugelassen als in anderen.</p>
<p class="contents">Mit dem neuen Kooperationsmechanismus könnten wir den Zugang zu neuesten und besten Medikamenten und Behandlungsmethoden für die Europäer*Innen beschleunigen und sicherstellen, dass diese auch in der ganzen Europäischen Union nach den gleichen Kriterien beurteilt werden. Das umfasst Medikamente, medizinische Geräte und Produkte wie Prothesen und künstliche Gelenke.</p>
<p class="contents">Gemeinsames europäisches Vorgehen in den Bereichen klinische Tests, wissenschaftliche Konsultation und Bewertung neuer Technologien am Markt macht die Prozesse nicht nur effizienter und schneller, sondern ermöglicht auch viel gründlichere Testverfahren, bevor ein Produkt auf dem Binnenmarkt zugelassen wird. Wir appellieren an den Rat, dies nicht länger zu verhindern.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-448-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124851.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:52:41&amp;playerEndTime=20190213-16:53:54" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicola Caputo (S&amp;D).</span></span>   – Signor Presidente, onorevoli colleghi, una percentuale molto elevata dei nuovi farmaci immessi sul mercato non presenta un evidente miglioramento tecnologico rispetto ai medicinali esistenti. La competizione si gioca spesso più sul nome del farmaco che sulla sua composizione. </p>
<p class="contents">Questo Parlamento ha lavorato molto all'introduzione della valutazione europea del valore terapeutico aggiunto dalla tecnologia sanitaria e all'armonizzazione dei criteri di valutazione clinica dei medicinali, che determinerebbero una maggiore qualità della ricerca e dell'innovazione e l'eliminazione di inutili duplicazioni. Se l'obiettivo è quello di un'armonizzazione legislativa che conduca ad un miglioramento della qualità del mercato dei farmaci, il sistema di valutazione delle tecnologie sanitarie non può essere su base volontaria, come vorrebbe la Germania. </p>
<p class="contents">Purtroppo, dopo un lungo iter legislativo, i cittadini europei non vedranno approvato definitivamente questo regolamento entro la fine della legislatura a causa della mancata unità d'intenti in seno al Consiglio. Con il voto di domani consegniamo al prossimo Europarlamento la nostra posizione definitiva, con la speranza che nell'interesse dei cittadini europei si riesca ad arrivare ad una posizione condivisa nel più breve tempo possibile. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-449-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/40599.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:53:55&amp;playerEndTime=20190213-16:55:14" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sirpa Pietikäinen (PPE).</span></span>   – Mr President, it’s extremely important that, this time, we do even better and more coherent work on health technology assessment than the Commission and Parliament have so far managed, because the regulatory framework is either disabling or enabling, depending on whether you look at it from the patient’s perspective, the user’s perspective or the competitiveness and business perspective.</p>
<p class="contents">If we have 28 different kinds of regulation, there’s always this unfair and unjust practice. Some get the applications and some do not, and you can’t create European e—health digital medical devices and medicines, to be provided for everybody, if you have 28 different kinds of regulation. So it is vital that we have an enabling European framework, with only very stringent exceptions, to be there for the patients’ and markets’ sake.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-450-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:55:13&amp;playerEndTime=20190213-16:55:24" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">Intervenții la cerere</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-451-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125069.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:55:22&amp;playerEndTime=20190213-16:56:29" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νότης Μαριάς (ECR).</span></span>   – Κύριε Πρόεδρε, οι τεχνολογίες υγείας είναι προφανές ότι πρέπει να στηρίζουν τον άνθρωπο, να στηρίζουν τον ασθενή, γιατί η υγεία είναι δημόσιο αγαθό. Όμως, όταν μπαίνει όλη η διαδικασία της ανάπτυξης τεχνολογιών υγείας στο πλαίσιο της εσωτερικής αγοράς, τότε το βασικό που πρυτανεύει είναι η αγορά. Μετατρέπεται, δηλαδή, η υγεία σε εμπόρευμα και μπαίνει στην υπηρεσία των πολυεθνικών ομίλων και των φαρμακευτικών εταιρειών. Πρέπει, λοιπόν, να πετύχουμε τεχνολογίες υγείας που να είναι υπέρ του ίδιου του ασθενή και να υπάρχουν φθηνά φάρμακα, προκειμένου να αντιμετωπίζουμε ουσιαστικά το κυρίαρχο πρόβλημα, που είναι η στήριξη της υγείας των ασθενών. Στην Ελλάδα δυστυχώς, η τρόικα, επιβάλλοντας τις δικές της πολιτικές, αφαίρεσε φάρμακα σημαντικά —όπως είναι τα φάρμακα κατά του καρκίνου— από το σύστημα υγείας. Πανάκριβα φάρμακα κατά του καρκίνου, τα οποία αδυνατούν οι έλληνες ασθενείς να προμηθευτούν.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-452-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:56:28&amp;playerEndTime=20190213-16:56:35" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(Încheierea intervențiilor la cerere)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-453-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:56:33&amp;playerEndTime=20190213-16:57:53" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Mr President, I have listened to your views with great interest and thank you for your overall, very strong support and I see that we are all like-minded here. I can assure you that the Commission will carefully analyse all the points raised by Members in today’s discussions.</p>
<p class="contents">Let me reiterate that the Commission is ready to provide its expertise to the European Parliament and the Council in order to support the negotiations and facilitate possible compromise solutions.</p>
<p class="contents">As has been recognised by the European Parliament, the proposed regulation will benefit a wide range of stakeholders, including Member State authorities, health technology developers, the healthcare providers and payers and, most importantly patients, across the EU. Equal treatment and equal access is the cornerstone when we are speaking about innovative treatment. I can assure of the full support of the Commission towards reaching an agreement on this important file.</p>
<p class="contents">Once again I thank you for your continued support, and let’s do our best to encourage Member States now to once again reassess their positions and move as soon as possible to final conclusions.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-454-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/33984.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20190213-16:57:52&amp;playerEndTime=20190213-16:58:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Președintele. – </span></span>  Dezbaterea a fost închisă.</p>
<p class="contents">Votul va avea loc mâine, 14.2.2019.</p>
<p class="contents"><span class="italic">(Ședința a fost suspendată pentru câteva momente în așteptarea votării.)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-455-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents" align="center"><span class="bold">PRESIDENZA DELL'ON. FABIO MASSIMO CASTALDO </span><br /><span class="italic">Vicepresidente</span></p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td>Last updated: 24 May 2019</td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
